Sana Biotechnology, Inc.
We were founded on the belief that engineered cells will be one of the most important transformations in medicine over the next several decades. The burden of diseases that can be addressed at their root cause through engineered cells is significant. We view engineered cells as having the potential to be as therapeutically disruptive as biologics to clinical practice. Our long-term aspirations are to be able to control or modify any gene in the body, to replace any cell that is damaged or missing, and to markedly improve access to cellular and gene-based medicines. We have brought together an experienced group of scientists, engineers, and company builders and combined them with the necessary technologies to move this vision forward.
We are developing in vivo and ex vivo cell engineering platforms to revolutionize treatment across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic disorders, among others. While our current product candidates are all in preclinical development, our goal is to file multiple investigational new drug applications (INDs) both in 2022 and 2023.
(Note: Sana Biotechnology upsized its IPO to 22 million shares at $23 to $24 – up from its initial terms of 15 million shares at $20 to $23 – in an S-1/A filing dated Feb. 3, 2021.)
|Address||188 East Blaine Street, Suite 400 Seattle, Washington 98102|
|Phone Number||(206) 701-7914|
|View Prospectus:||Sana Biotechnology, Inc.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-215.2 mil (last 12 months)|
|Price range||$25.00 - $25.00|
|Est. $ Volume||$587.5 mil|
|Manager / Joint Managers||Morgan Stanley/ Goldman Sachs/ J.P. Morgan/ BofA Securities|
|Expected To Trade:||2/4/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|